CL2014002181A1 - Entidad quimica derivada de pirazolopirimidina, inhibidora de la enzima activadora de ubiquitina; forma 1 cristalina anhidra; forma 2 cristalina monohidratada; composicion farmaceutica; metodo para tratar el cancer; y uso para el tratamiento de cancer de pulmones, cancer de ovarios, cancer de colon, cancer de mama o linfoma. - Google Patents

Entidad quimica derivada de pirazolopirimidina, inhibidora de la enzima activadora de ubiquitina; forma 1 cristalina anhidra; forma 2 cristalina monohidratada; composicion farmaceutica; metodo para tratar el cancer; y uso para el tratamiento de cancer de pulmones, cancer de ovarios, cancer de colon, cancer de mama o linfoma.

Info

Publication number
CL2014002181A1
CL2014002181A1 CL2014002181A CL2014002181A CL2014002181A1 CL 2014002181 A1 CL2014002181 A1 CL 2014002181A1 CL 2014002181 A CL2014002181 A CL 2014002181A CL 2014002181 A CL2014002181 A CL 2014002181A CL 2014002181 A1 CL2014002181 A1 CL 2014002181A1
Authority
CL
Chile
Prior art keywords
cancer
crystalline form
pyrazolopyrimidine
lymphoma
monohydrate
Prior art date
Application number
CL2014002181A
Other languages
English (en)
Spanish (es)
Inventor
Roushan Afroze
Indu T Bharathan
Jeffrey P Clavarri
Paul E Fleming
Jeffrey L Gaulin
Mario Girard
Steven P Langston
Francois R Soucy
Tzu-Tshin Wong
Yingshun Ye
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of CL2014002181A1 publication Critical patent/CL2014002181A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2014002181A 2012-02-17 2014-08-14 Entidad quimica derivada de pirazolopirimidina, inhibidora de la enzima activadora de ubiquitina; forma 1 cristalina anhidra; forma 2 cristalina monohidratada; composicion farmaceutica; metodo para tratar el cancer; y uso para el tratamiento de cancer de pulmones, cancer de ovarios, cancer de colon, cancer de mama o linfoma. CL2014002181A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261600070P 2012-02-17 2012-02-17

Publications (1)

Publication Number Publication Date
CL2014002181A1 true CL2014002181A1 (es) 2014-12-12

Family

ID=48982730

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002181A CL2014002181A1 (es) 2012-02-17 2014-08-14 Entidad quimica derivada de pirazolopirimidina, inhibidora de la enzima activadora de ubiquitina; forma 1 cristalina anhidra; forma 2 cristalina monohidratada; composicion farmaceutica; metodo para tratar el cancer; y uso para el tratamiento de cancer de pulmones, cancer de ovarios, cancer de colon, cancer de mama o linfoma.

Country Status (30)

Country Link
US (4) US9290500B2 (enExample)
EP (3) EP2814791A4 (enExample)
JP (1) JP6122877B2 (enExample)
KR (1) KR20140123104A (enExample)
CN (1) CN104136399B (enExample)
AR (1) AR092797A1 (enExample)
BR (1) BR112014020365B1 (enExample)
CA (1) CA2864672C (enExample)
CL (1) CL2014002181A1 (enExample)
CO (1) CO7071135A2 (enExample)
CR (1) CR20140380A (enExample)
DO (1) DOP2014000187A (enExample)
EA (1) EA035020B1 (enExample)
EC (1) ECSP14019113A (enExample)
ES (1) ES2739150T3 (enExample)
GE (1) GEP201706687B (enExample)
HK (1) HK1201817A1 (enExample)
IL (1) IL234016A0 (enExample)
MA (1) MA35932B1 (enExample)
MX (1) MX352963B (enExample)
NZ (1) NZ628969A (enExample)
PE (1) PE20142244A1 (enExample)
PH (1) PH12014501832A1 (enExample)
SG (2) SG10201606581RA (enExample)
TN (1) TN2014000351A1 (enExample)
TW (1) TWI593688B (enExample)
UA (1) UA116534C2 (enExample)
UY (1) UY34629A (enExample)
WO (1) WO2013123169A1 (enExample)
ZA (1) ZA201406103B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
UA116534C2 (uk) 2012-02-17 2018-04-10 Мілленніум Фармасьютікалз, Інк. Піразолопіримідинілові інгібітори убіквітинактивуючого ферменту
CN104684559A (zh) 2012-08-03 2015-06-03 米伦纽姆医药公司 针对Uba6的吲哚取代的吡咯并嘧啶基抑制剂
WO2015002994A2 (en) 2013-07-02 2015-01-08 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of sumo activating enzyme
BR112016030787B1 (pt) 2014-07-01 2022-12-20 Takeda Pharmaceutical Company Limited Entidade química, composição farmacêutica e seu uso
WO2016069393A1 (en) 2014-10-29 2016-05-06 Millennium Pharmaceuticals, Inc. Administration of ubiquitin-activating enzyme inhibitor and radiation
US20180133221A1 (en) 2014-10-29 2018-05-17 Millennium Pharmaceuticals, Inc. Administration of ubiquitin-activating enzyme inhibitor and chemotherapeutic agents
KR20250174699A (ko) 2018-10-30 2025-12-12 크로노스 바이오, 인코포레이티드 Cdk9 활성을 조절하기 위한 화합물, 조성물 및 방법
CN117412973B (zh) * 2021-05-31 2026-07-17 上海瑛派药业有限公司 含氮稠合杂芳双环化合物作为usp1抑制剂及其应用
WO2023021498A1 (en) * 2021-08-16 2023-02-23 Moya Bio Ltd. Fused azole and furan based nucleoside analogs and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003073989A2 (en) 2002-02-28 2003-09-12 Biota, Inc. Nucleoside 5'-monophosphate mimics and their prodrugs
KR20050058507A (ko) 2002-09-04 2005-06-16 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
DE60313872T2 (de) 2002-09-04 2008-01-17 Schering Corp. Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
WO2004087707A1 (en) 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
JP2005008581A (ja) 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ[1,5−a]ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
US20050130974A1 (en) 2003-10-17 2005-06-16 Rigel Pharmaceuticals, Inc. Benzothiazole compositions and their use as ubiquitin ligase inhibitors
US20050282818A1 (en) 2004-06-22 2005-12-22 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
WO2006084281A1 (en) 2005-02-04 2006-08-10 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
CN101321759A (zh) 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶化合物
HRP20120786T1 (hr) * 2006-02-02 2012-11-30 Millennium Pharmaceuticals, Inc. Inhibitori aktivirajuä†eg enzima e1
EP1992008A1 (en) * 2006-02-28 2008-11-19 Sez Ag Device and method for liquid treating disc-like articles
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
ME02789B (me) * 2006-08-08 2011-06-30 Millennium Pharm Inc Jedinjenja heteroarila korisna kao inhibitori e1 aktivirajućih enzima
CA2691987C (en) 2007-06-12 2016-08-16 Achaogen, Inc. Antibacterial agents
EP2540727B1 (en) 2007-08-02 2018-07-25 Millennium Pharmaceuticals, Inc. Sulfamoylating reagent
WO2009082691A1 (en) 2007-12-21 2009-07-02 Board Of Regents, University Of Texas System Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
EP2430026A1 (en) * 2009-05-14 2012-03-21 Millennium Pharmaceuticals, Inc. Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
CA2791738C (en) 2010-03-01 2020-06-09 Gtx, Inc. Aryl imidazolyl compounds for the treatment of cancer
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
MY166889A (en) 2011-08-24 2018-07-24 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
UA116534C2 (uk) 2012-02-17 2018-04-10 Мілленніум Фармасьютікалз, Інк. Піразолопіримідинілові інгібітори убіквітинактивуючого ферменту
CN104684559A (zh) 2012-08-03 2015-06-03 米伦纽姆医药公司 针对Uba6的吲哚取代的吡咯并嘧啶基抑制剂
WO2015002994A2 (en) 2013-07-02 2015-01-08 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of sumo activating enzyme
BR112016030787B1 (pt) 2014-07-01 2022-12-20 Takeda Pharmaceutical Company Limited Entidade química, composição farmacêutica e seu uso

Also Published As

Publication number Publication date
CR20140380A (es) 2014-10-28
WO2013123169A1 (en) 2013-08-22
SG10201606581RA (en) 2016-09-29
EP3536692A1 (en) 2019-09-11
TN2014000351A1 (en) 2015-12-21
JP2015508775A (ja) 2015-03-23
AR092797A1 (es) 2015-05-06
HK1201817A1 (en) 2015-09-11
US9663525B2 (en) 2017-05-30
CA2864672A1 (en) 2013-08-22
BR112014020365A2 (pt) 2020-12-22
MX2014009944A (es) 2014-11-10
EP2814791A1 (en) 2014-12-24
US20170217968A1 (en) 2017-08-03
EP3173413A1 (en) 2017-05-31
MA35932B1 (fr) 2014-12-01
TW201345909A (zh) 2013-11-16
CO7071135A2 (es) 2014-09-30
BR112014020365B1 (pt) 2023-02-23
TWI593688B (zh) 2017-08-01
MX352963B (es) 2017-12-15
US9290500B2 (en) 2016-03-22
EA201400831A1 (ru) 2014-12-30
US20170369499A1 (en) 2017-12-28
US20140088096A9 (en) 2014-03-27
US9796725B2 (en) 2017-10-24
KR20140123104A (ko) 2014-10-21
DOP2014000187A (es) 2014-10-15
IL234016A0 (en) 2014-09-30
PH12014501832A1 (en) 2014-11-17
NZ628969A (en) 2017-03-31
PE20142244A1 (es) 2015-01-07
ECSP14019113A (es) 2015-09-30
EP3173413B1 (en) 2019-05-01
GEP201706687B (en) 2017-06-26
CA2864672C (en) 2018-01-09
EP2814791A4 (en) 2015-08-19
EA035020B1 (ru) 2020-04-17
UA116534C2 (uk) 2018-04-10
ES2739150T3 (es) 2020-01-29
US10202389B2 (en) 2019-02-12
CN104136399A (zh) 2014-11-05
CN104136399B (zh) 2018-08-07
ZA201406103B (en) 2017-11-29
EP3536692B1 (en) 2021-04-07
SG11201404757WA (en) 2014-09-26
UY34629A (es) 2013-09-02
JP6122877B2 (ja) 2017-04-26
US20130217682A1 (en) 2013-08-22
US20160244455A1 (en) 2016-08-25

Similar Documents

Publication Publication Date Title
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
CL2014000511A1 (es) Compuestos derivados de quinazolina, inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7; proceso de preparacion; composiciones farmaceuticas que los contienen y el uso en el tratamiento y/o la prevencion de enfermedades tales como cancer.
HK1214815A1 (zh) Zeste增强子同源物2的抑制剂
CL2007003774A1 (es) Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis.
EA201600622A1 (ru) Бициклические анелированные гетероарильные или арильные соединения и их применение в качестве ингибиторов irak4
CL2015001250A1 (es) Compuestos derivados de triazolopirazinas, inhibidores de brd4; preparacion farmaceutica; y su uso en el tratamiento y/o la prevencion de cancer, tal como cancer de pulmon, higado, colon, cerebro, tiroides, mamas, entre otros.
HRP20220897T8 (hr) Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka
TN2015000516A1 (en) Chemical compounds
CL2012001627A1 (es) Compuestos derivados de 1,3-tiazol-fenilaminopirimidinas, inhibidores de syk; composición farmacéutica; y su uso para el tratamiento de la artritis reumatoide y cancer.
WO2013173441A3 (en) Enhancer of zeste homolog 2 inhibitors
EA201171367A1 (ru) Винилиндазолильные соединения
EA201400178A1 (ru) Лечение рака молочной железы
IL231835A0 (en) Pyrrolopyrimidine compounds for cancer treatment
CL2014001060A1 (es) Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades.
MA40076A (fr) Inhibiteurs de syk
CL2015003595A1 (es) Inhibidores/antiandrógenos novedosos de cyp17
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
SI3805233T1 (sl) (r)in (s) enantiomera n-(5-(3-hidroksipirolidin-1-il)-2-morfolinooksazolo(4,5-b)piridin-6-il) -2-(2-metilpiridin-4-il)oksazol-karboksamid kot inhibitorji irak4 za zdravljenje raka
CL2014002386A1 (es) Compuesto inhibidor de cinasa de fosfoinositida 3 en forma anhidra cristalina solida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento o prevencion de enfermedades tales como epoc, asma, entre otras.
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
EP3133073A3 (en) Inhibitors of iap
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
SG11201502795VA (en) Novel process for making compounds for use in the treatment of cancer